Tianjin CanSino Biotechnology Co., Ltd. is a participant of unrestricted biowarfare of Chinese People's Liberation Army

Basic Information

 Tianjin CanSino Biotechnology Co., Ltd.(天津康希诺生物技术有限公司), a participant of unrestricted biowarfare of Chinese People's Liberation Army, has published Prospectus Letter of Intent for Initial Public Offering on 23 July 2020. The prospectus provided verifiable detailed information about CanSino Biologics Inc(康希诺生物股份公司) or PLC(public limited company) that was transformed from former Tianjin CanSino Biotechnology Co., Ltd. on 13 Feb 2017 (hereafter referred to as CanSino ), ie a PLC transformed from the private limited company.

CanSino is a foreign-invested enterprise jointly established by five natural persons,  Xuan Liu(刘宣),  Tao Zhu(朱涛), DONGXU QIU(邱东旭), HELEN HUIHUA MAO(毛慧华)  and XUEFENG YU(宇学峰) numbersed as 1,2,3,4 and 5 in the shareholding structure.

On 29 December 2008, the five persons jointly signed the "Articles of Association of Sino-Foreign Joint Venture" and "Contract of Sino-foreign Joint Venture". The shareholding structure of the company on incorporation was as follows:

On 25 Jan 2017, Tianjin CanSino Biotechnology Co., Ltd. was transformed into CanSino Biologics Inc, upon deliberation at the fifth meeting of the sixth session of the Board of Directors, based on the book net assets of 222,000,345.63 yuan as of 30 November 2016 which were converted into 129,878,265 ordinary shares of the PLC with a face value of 1 yuan per share with a different shareholding structure.

It is a company dedicated to the research and development, production and sales of vaccines. The research and development pipeline covers the prevention of meningitis, Ebola virus disease, DTP, pneumonia, tuberculosis, new coronavirus (COVID-19), herpes zoster and other clinical Varieties of vaccines in high demand.

Among them, Ebola virus disease vaccine has completed new drug registration, two meningococcal vaccine products have been submitted for NDA and accepted, DTP vaccine, pneumonia vaccine, tuberculosis vaccine, recombinant new coronavirus vaccine (adenovirus vector) have entered the market. clinical trial stage.

The products focus on three major areas of meningitis, DTP and pneumonia, including MCV4, MCV2, DTcp for infants, DTcP booster vaccine, Tdcp for adolescents and adults, DTcP-Hib combination vaccine, PBPV and PCV13i.

Associations with Chinese People's Liberation Army

After the outbreak of Ebola virus in 2014, the Institute of Bioengineering of the Academy of Military Sciences and the company carried out cooperative research on Ad5-EBOV. According to the cooperation arrangement, the Institute of Bioengineering of the Academy of Military Sciences cooperates with the company to evaluate the immunogenicity and safety of EBOV, conduct clinical trials, submit the registration application of Ad5-EBOV, and the company is responsible for the production of the product. The company and the Institute of Bioengineering of the Academy of Military Sciences have jointly obtained the new drug certificate, and the company has obtained the drug production approval. At present, this product is only intended for emergency use and national reserves, and needs to be used under the guidance of the relevant national health management departments.

From January 2016 to December 2016, the company and the Institute of Bioengineering, Academy of Military Sciences jointly undertook the development of recombinant Ebola virus disease vaccine and phase I clinical research on Chinese population and African population in China.

From January 2018 to December 2020, the company undertook the sub-project of the National Science and Technology Major Project "Clinical and Industrialization of Ebola Vaccine and Preclinical Research of Zika Vaccine" .Responsible entity: Institute of Bioengineering, Academy of Military Sciences; Responsibilities of CanSino: Completed the industrialization research of Ebola vaccine, including obtaining the new drug certificate for recombinant Ebola virus disease vaccine and production approval.

The company has jointly developed a recombinant novel coronavirus vaccine (adenovirus vector) with the Institute of Bioengineering, Academy of Military Medical Sciences, Academy of Military Sciences of the Chinese People's Liberation Army. It expresses the novel coronavirus S antigen and is intended to be used to prevent diseases caused by novel coronavirus infection. At present, the vaccine has been clinically approved, and the Phase II clinical trial started in April 2020, and the Phase II clinical trial research data was obtained in June 2020.

Ad5-EBOV, Merck VSV-EBOV recombinant Ebola virus disease vaccine was jointly developed by Institute of Bioengineering, Academy of Military Medicine, Academy of Military Sciences and CanSino. As of the signing date of this prospectus, the company has obtained a new drug certificate for the "recombinant Ebola virus disease vaccine (adenovirus vector)" jointly obtained with the Institute of Bioengineering, Academy of Military Sciences. Both parties agreed that CanSino will conduct related drug production. 

Suspected technology transferring from cooperation partners to Chinese People's Liberation Army

On 4 Sep 2018, the company entered into a master cooperation agreement with Vaccitech Limited. Under the Vaccitech Master Cooperation Agreement,follow-up cooperation projects include herpes zoster, HPV, influenza, MERS (Middle East respiratory syndrome coronavirus), hepatitis B, etc. As part of Vaccitech's Master Collaboration Agreement, on 4 September 2018, the company entered into a program agreement with Vaccitech for a shingles vaccine (ChAdOx Shingles Program Agreement). The company had made a £50,000 down payment to Vaccitech, which was still in preclinical studies.

On 28 May 2019, the company and Austrian biotechnology company BIRD-C signed a "bacterial ghosts" (BGs) vaccine technology research and development cooperation agreement. "Bacterial slough" refers to the bacterial empty shell of Gram-negative bacteria after lysis, which is not only an ideal vaccine antigen, but also an ideal antigen carrier to improve the immune effect of the vaccine. The cooperation between the two parties will start with technical exchanges, and will be followed by strategic cooperation in the development and commercialization of the "Bacteria" vaccine. Through the collaboration, the two parties will work to explore BGs as independent adjuvants for CanSinoBio's vaccines under development, and as neoantigens expressed in E. coli vectors.

Main Customers

In 2018, the company realized an income of 2.8119 million yuan, including 1.4378 million yuan for the sale of vaccine components for VaxYnethic S.r.l., and 1.1321 million yuan for toxin protein synthesis and in vivo research services for Suzhou Kangning Jierui Biotechnology Co., Ltd. In 2019, the company achieved an income of 2.2834 million yuan, of which 2.2627 million yuan was provided for the sale of vaccine components for VaxYnethic S.r.l., accounting for 99.09% of the current sales.

The main production equipment includes: ultrafiltration pure water preparation system, automatic sterilization fermenter system, vacuum freeze dryer, bioreactor system, Alfa Laval Clara200 centrifuge module, ion chromatograph, automatic microorganism identification system, high performance capillary electrophoresis Instrument, fixed automatic feeding and discharging, supporting active isolation system, capillary differential scanning calorimeter.

Background of founders and senior management as suspected theives of vaccine and drug technologies

XUEFENG YU, born in 1963, Canadian nationality, doctoral degree in microbiology; from 1988 to 1991, lecturer in the Department of Microbiology, Department of Biology, Nankai University; from 1991 to 1997, studied microbiology in the Department of Botany at McGill University Professional Doctorate; 1996-1998, Scientist of IBEX Technologies Inc.; 1998-2009, Scientist of Product Development Department of Sanofi Pasteur Limited., Global Director of Bacterial Vaccine Development, Canadian Fermentation Development director; since 2009, he has been the chairman, chief executive officer and general manager of CanSino, and is currently mainly responsible for the company's overall strategic development planning, overall operation management, and major decision-making management.

Tao Zhu, born in 1973, Chinese nationality, permanent residency in Canada, Ph.D. in chemical engineering, postdoctoral fellow at Carnegie Mellon University; 2004-2005, scientist at Integrated Genomics Inc;From 2006 to 2008, he served as a scientist and senior scientist at Sanofi Pasteur Limited. From 2009 to present, he has been the executive director, chief scientific officer and deputy general manager of CanSino, currently mainly responsible for management Matters related to vaccine research and development projects, including research and development progress, clinical trials, technical improvement, etc.; was elected as a member of the 13th National Committee of the Chinese People's Political Consultative Conference in January 2018.

DONGXU QIU, born in 1960, Canadian nationality, holds a permanent residence ID card for foreigners of the People's Republic of China, a doctor of pharmacy, a postdoctoral fellow in chemical engineering at Konstanz University in Germany, and a postdoctoral fellow at the University of Montreal in Canada; From 1993 to 1998, he served as a scientist and deputy director of Biomira, Canada; from 1999 to 2000, he was the director of the Altarex department; from 2000 to 2002, he was the director of scientific operations of ARIUS Research; 2003 to 2005 , served as the president of MDS CAPITAL Asia; from 2006 to 2009, served as the deputy general manager of Shanghai Gema Pharmaceutical Technology Co., Ltd.; from 2007 to 2011, served as the general manager of China Bio in the United States; Since 2009, he has served as executive director and deputy general manager of CanSino

SHOUBAI CHAO, born in 1962, American nationality, Ph.D. in biochemical engineering; from 1992 to 1993, worked as a bioprocess engineer of Philom Bios;From 1993 to 2000, he served as technical manager of bacterial vaccines and quality assurance manager of Sanofi-Aventis Group; in 2000, served as senior manager of quality management of Genentech; from 2001 to 2007, served as assistant general manager of vaccine technology of Wyeth Pharmaceuticals ; From 2008 to 2018, served as the vice president and senior vice president of AstraZeneca Pharmaceuticals; since 2018, he has served as the executive director, chief operating officer and deputy general manager of CanSino.

Jieyu Zou, born in 1989, Chinese nationality, master of public health; from 2012 to 2014, worked as a research assistant in Michael Allen Company; from 2014 to 2015, worked in Fosun High-Tech Group Investment Manager of Co., Ltd.; since 2015, he has served as Lilly Asia Fund Investment Manager, Senior Investment Manager, and Vice President; since 2016, he has served as Supervisor of CanSino.

HELEN HUIHUA MAO, born in 1962, Canadian nationality, permanent residency in the United States, Ph.D. in chemical engineering, post-doctoral fellow at the University of Waterloo in Canada; from 1990 to 1999, he was a development engineer in the American O'Bright Company;From 2000 to 2001, he was an APOTEX facility and equipment qualification expert; from 2001 to 2005, he was the quality management director of Wyeth Pharmaceuticals, USA; from 2006 to 2011, he was the global quality management director of Endo Pharmaceuticals Inc.; Director of CanSino and currently the company's deputy general manager.